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Objective: To evaluate the effect of carbon dioxide on the susceptibility testing, using broth microdilution and the Etest 
(AB Biodisk, Solna, Sweden), alf azithromycin, clarithromycin and roxithromycin against Streptococcus pneumoniae and 
Streptococcus pyogenes. 
Methods: Fresh clinical isolates collected from 36 hospital laboratories in 12 countries were evaluated using the Etest 
in the presence of carbon dioxide. The isolates were retested under ambient conditions (absence of carbon dioxide) 
using broth microdilution and/or the Etest. 
Results: Carbon dioxide falsely elevated azithromycin, clarithromycin and roxithromycin MICgos for S. pneumoniae, 
determined by the Etest, approximately 12-fold. Also, the azithromycin for S. pyogenes was increased fourfold; 
the effect was less marked for clarithromycin and roxithromycin. When isolates were retested in the absence of carbon 
dioxide, using the Etest or microdilution, susceptibilities to azithroymycin were comparable to those to clarithromycin 
(S. pneumoniae, 93.4% versus 91.3%; S. pyogenes, 96.4% versus 95.8%). Both organisms were less susceptible to 
roxithromycin (S. pneumoniae, 71.3%; S. pyogenes, 85.7%). An internal standard control, consisting of 50 isolates each 
of S. pneumoniae, S. pyogenes and Haemophilus influenzae, confirmed that azithromycin susceptibility testing resulted 
in falsely elevated MICs. 
Conclusions: Carbon dioxide falsely elevated azithromycin MlCs for S. pneumoniae and S. pyogenes, with an apparent 
reduction in susceptibility. When the in vitro activity of azithromycin and other macrolides against S. pneumoniae and 
S. pyogenes is being evaluateld, awareness of the pH effect is essential. 
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INTRODUCTION 
The Artemis Project is an ongoing in vitro surveillance 
study, conducted in over 401 countries and involving 
120 investigator sites, that cornpares the activities of azi- 
thromycin and other antimicrobial agents with similar 
spectra of activity against fresh clinical isolates. The 
comparative susceptibilities provided by the project will 
assist physicians in choosing the most appropriate 
antimicrobial therapy. The aim is to  demonstrate any 
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demographic and geographic patterns of susceptibility 
and identify any emerging resistance over time. 
Structural differences in azithromycin, a 15- 
membered-ring azalide, compared with the 14- 
membered-ring macrolides clarithromycin and roxithro- 
mycin, contribute to azithromycin's increased tissue 
uptake and slow release [l], and allow once-daily 
dosing for 3 or 5 days [2,3]. In vitro, azithromycin is 
highly active against Gram-positive organisms, includ- 
ing Streptococcus pneumoniae, Streptococcus pyogene and 
Staphylococcus aureus [4-61, Gram-negative aerobes, most 
notably Haemophilus influenzae [7,8], and atypical respir- 
atory pathogens [9], compared with other macrolides. 
Susceptibdity is most commonly determined world- 
wide by disk diffusion [lo], but, recently, broth micro- 
dilution testing has become the reference standard. Many 
efforts have been made to standardize testing across 
countries; however, most diagnostic laboratories still 
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retain their local methodology [Il l .  The Etest (AB 
Biodisk, Solna, Sweden), which combines the concepts 
of the broth dilution and dxk Musion methods, enables 
the direct determination of MICs and generally yields 
similar results to those obtained with broth microdilution 
and the disk diffusion test [12,13]. For this reason, it was 
the method selected for the Artemis Project. 
During phase I of the Project, significantly higher 
MICs of azithromycin for Streptococcus pneumoniae and 
Streptococcus pyogenes were noted in the presence of 
carbon dioxide, compared with roxithromycin and 
clarithromycin. Consequently, a study was performed 
to evaluate the effects of carbon dioxide on azithro- 
mycin susceptibility testing of globally collected fresh 
clinical isolates using both the Etest and broth 
microdilution. 
MATERIALS AND METHODS 
Clinical isolates 
Investigators at the 36 laboratories in Belgium, France, 
Germany, The Netherlands, Spain, Sweden, Argentina, 
Brazil, Chile, Mexico, Venezuela and Canada each 
collected and identified 500 fresh clinical isolates over 
a 4-month period banked or frozen isolates were not 
permitted. 
Laboratory testing 
Each laboratory was provided with detailed instruc- 
tions, examples of the Etest methodology, and Etest 
strips for azithromycin, clarithromycin and roxithro- 
mycin [14]. Strips were stored unopened at -20°C and 
protected from moisture at all times. Each laboratory 
was also given agar plates (blood agar) and Mueller- 
Hinton broth medium for susceptibility testing. The 
turbidity of the inoculum suspension in broth culture 
was adjusted to 0.5 Mcfarland standard, and was con- 
firmed by colony count. Plates were incubated at 35OC 
for 18-24 h in the presence of carbon dioxide. 
After subculture to chocolate agar slant and 
incubation for 15-18 h, all isolates were shipped to a 
central laboratory (International Health Management 
Associates, Inc. (IHMA, Inc.), Chicago, Illinois, USA) 
for quality control and random retesting of a 10% 
sample using NCCLS guidelines for a frozen micro- 
&lution panel. The antimicrobial breakpoints for 
Streptococcus pneumoniae used for data analysis followed 
NCCLS guidelines based on broth microdilution under 
ambient conditions [13]. The MIC interpretive stand- 
ards of azithromycin for streptococci are 10.5, 1 and 
2 2  mg/L for susceptible, intermediate and resistant, 
respectively. The susceptibility standards for clarithro- 
mycin and roxithromycin are one dilution lower 
than for azithromycin. Standard ATCC control strains 
(Streptococcus pneumoniae ATCC 49619, H. injluenzae 
ATCC 49247) were included as positive controls in 
each test. 
An internal standard control was also performed, 
and included 50 isolates each of H. influenme, Strepto- 
coccus pneumoniae and Streptococcus pyogenes. MICs were 
determined using both the Etest and broth micro- 
dilution under ambient conditions (absence of carbon 
dioxide) and with carbon dioxide incubation. Before 
and after each incubation, the pH was measured. 
RESULTS 
Eight hundred and fifty-three Streptococcus pneumoniae 
and 61 4 Streptococcus pyogenes isolates were collected, 
mainly from outpatients, and most frequently from 
the respiratory tract. The MIC5os of azithromycin, 
clarithromycin and roxithromycin for Streptococcus 
pneumoniae determined using the Etest in a 5% carbon 
dioxide atmosphere were 0.5, 0.64 and 0.19 mg/L, 
respectively (Table 1), and for Streptococcus pyogenes were 
0.5, 0.047 and 0.19 mg/L, respectively. The MIC90 
values for Streptococcus pneumoniae were 6.0, 3.0 and 12 
mg/L, and for Streptococcus pyogenes they were 1.5, 
0.125 and 5 mg/L, respectively. 
Retesting of Streptococcus pneumoniae (n=610) in 
the absence of carbon dioxide by broth microdilution 
yielded MIC90s of azithromycin, clarithromycin and 
roxithromycin for Streptococcus pneumoniae that were 12- 
fold lower than in its presence (Table 1). Similarly, a 
reduction in MICso values was noted when they were 
determined in the absence of carbon dioxide. In a 5% 
carbon dioxide atmosphere, only 53.8% of isolates were 
susceptible to azithromycin, compared with 87.1% for 
clarithromycin, whereas on retesting in a carbon 
dioxide-free atmosphere, the incidence of susceptibility 
of Streptococcus pneumoniae isolates to azithromycin was 
comparable to that of clarithromycin (93.4% versus 
91.3%, Table 1). The incidence of susceptibility of 
Streptococcus pneumoniae to roxithromycin was consider- 
ably lower (67.1% in the presence of carbon dioxide 
and 71.3% in its absence). 
In the case of Streptococcus pyogenes isolates, azithro- 
mycin MICs were fourfold lower when determined by 
the Etest in the absence of carbon dioxide compared 
with in its presence (Table 1). By contrast, clarithro- 
mycin and roxithromycin MIC values for Streptococtus 
pyogenes were less noticeably afTected by carbon &oxide. 
In the presence of carbon dioxide, only 55.2% of 
isolates were susceptible to azithromycin, but 96.4% 
were susceptible when incubation was performed with- 
out carbon dioxide. This incidence of susceptibility was 
comparable to the 95.8% recorded for clarithromycin 
(Table 1). The value for roxithromycin was lower 
(85.7%). 
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Table 1 Susceptibilities on retesiing of Streptococcus 
pneumoniae and Streptococcus pvopenes 
Azithro- Clarithro- Roxithro- 
mycin mycin mycin 
Streptococcus pneumoniae 
Etest+CO2 (n=853) 
MIC;o (mg/L) 
MICw (mg/L) 
Susceptible (%) 
Intermediate (“YO) 
Resistant (%) 
Broth microdilution 
-COz (n=610) 
MICso (mg/L) 
MICYIJ (mg/L) 
Susceptible (%) 
Intermediate (96) 
Resistant (“YO) 
Streptococcus pyogenes 
Etest + CO2 (n=  6 14) 
MICjo (mg/L) 
MIC9o (mg/L) 
Susceptible (%) 
Intermediate (“YO) 
Resistant (“h) 
MICso (mg/L) 
MIGO (mg/L) 
Susceptible (%) 
Intermediate (“A) 
Resistant (%) 
Etest-COz (n=504) 
0.5 
6.0 
53.8 
30.5 
15.7 
0.12 
0.5 
93.4 
3.9 
2.6 
0.5 
1.5 
55.2 
35.2 
9.6 
0.094 
0.38 
96.4 
0.8 
2.8 
0.64 
3.0 
87.1 
1.3 
11.6 
0.06 
0.25 
91.3 
1.1 
7.5 
0.047 
0.125 
96.1 
0.8 
2.8 
0.034 
0.094 
95.8 
1.2 
3.0 
0.19 
12.0 
67.1 
18.3 
14.6 
0.25 
1 .0 
71.3 
15.4 
13.3 
0.19 
0.5 
91.5 
4.9 
3.6 
0.125 
0.38 
85.7 
11.4 
3.0 
In the internal standard control study, the mean pH 
of microtiter plates was 7.22 afer equilibration for 2 h. 
Following incubation in the presence of carbon dioxide 
for 18 h, pH values fell, on average, by 0.46 units, 
compared with a reduction of only 0.10 units when no 
carbon dioxide was present. With agar plates, the pH 
was 7.27 prior to incubation; this value decreased by 
0.46 units in the presence of‘ carbon dioxide and by 
only 0.11 units in its absence. Comparable azithro- 
mycin, clarithromycin and roxithromycin MICs for H. 
inzuenzae, Streptococcus pneurnoniae and Streptococcus pyo- 
genes were detected by the Etest and broth microdilu- 
tion when incubation was done in the absence of 
carbon dioxide. The MICs for all three study drugs 
were elevated by both methods if incubation was 
performed with carbon dioxide present. The one 
exception was clarithromycin; there was no increase in 
the MIC90s in the presence of carbon dioxide deter- 
mined by the Etest when tested against Streptococcus 
pneurnoniae (Table 2). 
DISCUSSION 
Susceptibility testing can be affected by many factors, 
such as medium pH [15], agar depth [11], inoculum 
size [16], enrichment broth, mineral ion concentration 
[17] and carbon dioxide [18]. When carbon dioxide is 
present, carbonic acid forms on the surface of the agar 
or in the broth, causing a reduction in pH [19]. The 
Etest eliminates many of these variables and provides a 
standardized, relatively simple diffusion test. However, 
with this procedure, the MICs of macrolides, and 
specifically of azithromycin, for pathogens requiring 
carbon dioxide are falsely elevated. 
The NCCLS guidelines for Streptococcus pneurnoniue 
recommend microdilution performed in air, but state 
the need for carbon dioxide for disk diffusion testing 
[20]. Similarly, AB BIODISK recommends carbon 
dioxide for Etests. However, an international supple- 
ment to the Etest package insert for azithromycin shows 
adjusted ranges and interpretative breakpoints for both 
ambient and carbon dioxide incubation. It states that 
azithromycin MICs for Streptococcus pneurnoniue are 
three dilutions higher, and for H. influenzae one or two 
dilutions higher, when Etest methodology is performed 
Table 2 MIC9o internal standard control test consisting of 50 randomly selected isolates each of H. injuenzae, Streptococcus 
pneumoniae and Streptococcus pyogerws incubated in the presence or absence of carbon dioxide and tested by Etest and broth 
microdilution 
Etest Broth microdilution 
MIC9o (mg/L) MICW (mg/L) 
Organism Antibiotic +COz -COz +COz - CO2 
Haemophilus injuenzae Azithromycin 8.0 2.0 4.0 2.0 
Clarithromycin 16.0 8.0 16.0 8.0 
Iloxithromycin 24.0 16.0 16.0 16.0 
Streptococcus pneumoniae Azithromycin 1 .o 0.25 2.0 0.25 
Clarithromycin 0.094 0.094 0.5 0.12 
lloxithromycin 0.5 0.25 6.0 0.5 
Streptococcus pyogenes Azithromycin 1.5 0.25 2.0 0.25 
Clarithromycin 0.125 0.032 0.25 0.06 
Iloxithromycin 0.5 0.19 1.0 0.25 
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in the presence of carbon dioxide. There is clearly a 
need for macrolide breakpoints for both methods in the 
presence and absence of carbon dioxide. This is partic- 
ularly important, as about 10% of pneumococcal strains 
do not grow in air on primary isolation. The situation 
for Streptococcus pyogenes is different, as there are, at 
present, no established breakpoints for Streptococcus 
pyogenes. 
Results obtained &om the Artemis Project demon- 
strate that the Etest significantly underestimates the 
potency of azithromycin when incubations are per- 
formed in a carbon dioxide atmosphere. When inter- 
preting Etest MIC values according to the manufacturer’s 
carbon dioxide-adjusted breakpoints, the majority of the 
intermediate (approximately 30%) and resistant (7-13%) 
strains would be classified as susceptible. The suscept- 
ibility data for Streptococcus pyogenes determined by 
NCCLS procedures corresponded with those &om the 
Etest in the presence of carbon dioxide for clarithro- 
mycin and roxithromycin. In the case of azithromycin, 
carbon dioxide falsely increased Streptococcus pneumoniae 
MICs 12-fold and Streptococcus pyogenes values fourfold 
due to a change in the pH of the medium. A previous 
study showed that a 5% carbon dioxide atmosphere 
resulted in the pH being lowered by 0.4 unit (&om 
7.3 to 6.9) after incubation for 18 h, and resulted in 
MICs for Gram-positive organisms that were higher than 
normal [XI.  During phase I of the Artemis Project, the 
internal standard control confirmed that investigator- 
analyzed isolates in the presence of carbon dioxide had 
increased MICs (approximately 2-1 2-fold) compared 
with isolates that were retested in the central laboratory 
in the absence of carbon dioxide. 
To ensure accurate susceptibility testing of azithro- 
mycin or other macrolides against Streptococcus pneu- 
rnoniae, Streptococcus pyogenes and H. injuenzae, ambient 
incubation without carbon dioxide is mandatory. The 
alternative would be to develop macrolide breakpoints 
for both air and carbon dioxide incubation for all 
methods of testing. This would be particularly applic- 
able to the 10% of pneumococci that do not grow in 
air on primary isolation. 
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